白雲山(600332.SH):子公司《藥品生產許可證》變更
格隆匯11月5日丨白雲山(600332.SH)公佈,子公司廣州白雲山奇星藥業有限公司(以下簡稱“奇星藥業”)收到廣東省藥品監督管理局核准簽發的《藥品生產許可證》,同意奇星藥業委託廣州白雲山中一藥業有限公司(以下簡稱“中一藥業”)生產蛇膽川貝散、喉康散和複方餘甘子利咽含片,委託廣州白雲山醫藥集團股份有限公司白雲山製藥總廠(以下簡稱“白雲山製藥總廠”)生產健脾補血顆粒,本次奇星藥業委託中一藥業和白雲山製藥總廠生產藥品,有利於本公司優化資源配置,繼續保持穩定的生產能力,滿足市場需求,本次獲得《藥品生產許可證》,對本公司當期業績無重大影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.